EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development

Helena Kontola iD, Luís Crisóstomo iD, Eliisa Löyttyniemi iD, Jaakko J Koskenniemi iD, Riitta Veijola iD, Jorma Toppari iD, Jukka Kero iD

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgaf601 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Helena Kontola und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pediatrics, Turku University Hospital, Turku FIN-20500, Finland. Hauptthemen laut MEDLINE: Glucagon, Diabetes Mellitus, Type 1, Glucose. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 44 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Sigrid Juselius Foundation, Finland, Pediatric Research Foundation, Turku University Hospital Special Governmental Funding.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Autoimmune destruction of β cells and their functional decline precedes the clinical onset of type 1 diabetes. However, altered α-cell function and hyperglucagonemia may contribute to the development of hyperglycemia and ketoacidosis at onset.

Objective

In this cross-sectional study, we analyzed glucagon concentrations during an oral glucose tolerance test (OGTT) in individuals at the early stages of type 1 diabetes to understand the role of α-cell function in the disease process.

Methods

We recruited 47 participants, aged 4 to 25 years, from the Finnish Diabetes Prediction and Prevention (DIPP) study, and categorized them into the following groups: islet autoantibody (IAb) negative, single IAb positive, and stages 1 to 3 of type 1 diabetes. Glucagon levels were measured during a 6-point OGTT using a conventional radioimmunoassay, alongside insulin, C-peptide, glucose, and glucagon-like peptide-1 (GLP-1).

Results

Fasting plasma glucagon levels increased with disease progression. The longitudinal patterns of glucagon concentrations during the OGTT differed significantly between groups, with a paradoxical 15-minute glucagon increase observed only in individuals at early stage 3 of type 1 diabetes.

Conclusion

These findings highlight the need for prospective studies to further elucidate the role of α cells in disease progression and support testing pharmacotherapies aimed at improving both α- and β-cell functions during disease development.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

GlucagonDiabetes Mellitus, Type 1GlucoseHumansMaleFemaleCross-Sectional StudiesChildGlucose Tolerance TestAdultAdolescentChild, PreschoolYoung AdultDisease ProgressionBlood GlucoseAutoantibodiesInsulinGlucagon-Secreting CellsC-PeptideGlucagon-Like Peptide 1

Stichwörter der Autor:innen

hyperglucagonemiapancreatic isletprediabetesα cells

Substanzen

GlucagonBlood GlucoseAutoantibodiesInsulinC-PeptideGlucoseGlucagon-Like Peptide 1

Autor:innen und Institutionen

  • Department of Pediatrics, Turku University Hospital, Turku FIN-20500, Finland.
  • Medicity Research Laboratory, University of Turku, Turku FIN-20500, Finland.
  • InFlames Research Flagship, Institute of Biomedicine, University of Turku, Turku FIN-20500, Finland.
  • Department of Biostatistics, University of Turku and Turku University Hospital, Turku FIN-20500, Finland.
  • Health Informatics Institute, University of South Florida, Tampa, FL 33512, USA.
  • Department of Children and Adolescents, Oulu University Hospital, Oulu FIN-90220, Finland.

ORCID-Profile: Helena Kontola, Luís Crisóstomo, Eliisa Löyttyniemi, Jaakko J Koskenniemi, Riitta Veijola, Jorma Toppari, Jukka Kero

Förderung

  • Sigrid Juselius Foundation, Finland
  • Pediatric Research Foundation
  • Turku University Hospital Special Governmental Funding
  • TYKS foundation
  • Turku University Foundation
  • The Alma and K.A. Snellmann Foundation
  • JDFR International; Kyllikki and Uolevi Lehikoinen's Foundation
  • Foundation for Pediatric Research, and Finnish Cultural Foundation

Zitieren

APA

Kontola, H., Crisóstomo, L., Löyttyniemi, E., Koskenniemi, J. J., Veijola, R., Toppari, J., & Kero, J. (2025). Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgaf601

Vancouver

Kontola H, Crisóstomo L, Löyttyniemi E, Koskenniemi JJ, Veijola R, Toppari J, et al. Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgaf601

BibTeX
@article{Kontola2025,
  author = {Kontola, Helena and Crisóstomo, Luís and Löyttyniemi, Eliisa and Koskenniemi, Jaakko J and Veijola, Riitta and Toppari, Jorma and Kero, Jukka},
  title = {Altered Glucagon Response to Oral Glucose in Individuals at Different Stages of Type 1 Diabetes Development},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgaf601}
}
Kostenlos starten →